NOVEL ANTICOAGULANTS BEYOND HEPARIN AND WARFARIN

Akbar Basha S; Abdul Kareem S

doi:10.22159/ajpcr.2018.v11s4.31690

Authors

Akbar Basha S Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamil Nadu, India
Abdul Kareem S Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamil Nadu, India

DOI:

https://doi.org/10.22159/ajpcr.2018.v11s4.31690

Keywords:

Anticoagulation, Apixaban, Dabigatran, Novel drugs, Rivaroxaban, Warfarin

Abstract

Objective: The objective of the study is to know about newer anticoagulant drugs.
Method: The Vitamin K adversaries are the single type of oral anticoagulant in the pharmaceutical, and which is endorsed for long-haul utilize.
What is more, the Vitamin K adversaries are exceedingly successful, so it is utilized to avert, and treatment of most thrombotic infections in patients,
the noteworthy interpatient and intrapatient are additionally fluctuation in measurement response, and the thin restorative medication record and
the more quantities of medication and dietary communications related with these specialists have lead clinicians, patients, and examiners to scan
for different operators. The three new orally controlled anticoagulants are apixaban, dabigatran, and rivaroxaban, which are in the late periods of
progression and a couple of others they are basically entering (or traveling through), the earlier times of examinations. Those most recent anticoagulant
drugs are being contemplated just for the avoidance and furthermore the treatment of venous for the thromboembolism, and the treatment of intense
coronary conduit disorders, and furthermore the counteractive action of stroke in patients influenced by atrial fibrillation.
Results: The pharmacological action of the three new orally controlled anticoagulants is apixaban, dabigatran, and rivaroxaban completely reviewed
and compared with warfarin.
Conclusion: We are compared the newer anticoagulant with warfarin and discussed about advantages of newer anticoagulants.

Downloads

Download data is not yet available.

References

Goodman LS, Gilmans AS. Goodman and Gilmans the Pharmacological Basis of the Therapeutics. 11th ed. New York: McGraw Hill; 1941. p. 937.

Medscape.com. Available from: https://www.emedicine.medscape.com/article/1926110-overview. [Last accessed on 2018 Jan 18].

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014;383:955-62.

Lawrence LK. New Anticoagulants. Available from: https://www.uptodate.com/contents/direct-oral-anticoagulants-and-parenteral-direct-thrombin-inhibitors-dosing-and-adverse-effects. [Last accessed on 2012 Nov 08].

Agnelli G. Venous thromboembolism and cancer: A two way clinical association. Thromb Haemost 1997;78:117-20.

Bauer KA. Fondaparinux: Basic properties and efficacy and safety in venous thromboembolism prophylaxis. Am J Orthop 2002;31:4-10.

Davidson B. Preparing for the new anticoagulants. J Thromb Thrombolysis 2003;16:49-54.

Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: A controlled trial. Lancet 1960;1:1309-12.

Walenga JM, Hoppensteadt DA. Monitoring the new antithrombotic drugs. Semin Thromb Hemost 2004;30:683-95.

Plovanich M, Mostaghimi A. Novel oral anticoagulants: What dermatologists need to know. J Am Acad Dermatol 2015;72:535-40.

Waugh A, Grant A, Waugh A. Ross and Wilson, Anatomy and Physiology in Health and Illness. 12th ed. United Kingdom: Elsevier e-Book Publication; 2018. p. 61.

Dager WE, Gulseth MP. Anticoagulation Therapy. ???: ???; 2011. p. 45-8.

Rose A. Anticoagulantion Management. 1st ed. Switzerland: ADIS Publisher; 2015. p. 53-77.

Alquwaizani M, Buckley L, Adams C, Fanikos J. Anticoagulants: A review of the pharmacology, dosing, and complications. Curr Emerg Hosp Med Rep 2013;1:83-97.

Oâ€™Sullivan EF. Duration of anticoagulant therapy in venous thromboembolism. Med J Aust 1972;2:1104-7.

Dundon JM, Trimba R, Bree KJ, Woods CJ, Laughlin RT. Recommendations for perioperative management of patients on existing anticoagulation therapy. JBJS Rev 2015;3:1874474.

Froom P, Miron E, Barak M. Oral anticoagulants in the elderly. Br J Haematol 2003;120:526-8.

Health Line. Available from: https://www.healthline.com/health/anticoagulant-and-antiplatelet-drugs#modal-close. [Last accessed on 2018 Jan 20].

Einstein Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.

Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the ARISTOTLE trial. Eur Heart J 2015;36:1264-72.

Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest 1986;89:16-25.

Available from: http://www.asheducationbook.hematologylibrary.org/cgi/reprint/2006/1/450.

Schutgens RE, van der Heijden JF, Mauser-Bunschoten EP, Mannucci PM. New concepts for anticoagulant therapy in personswith hemophilia. Blood 2016;128:24714.

Coon WW, Willis PW III, Symons MJ. Assessment of anticoagulant treatment of venous thromboembolism. Ann Surg 1969;170:559-68.

Harter K, Levine M, Henderson SO. Anticoagulation drug therapy: A review. West J Emerg Med 2015;16:11-7.

Marder VJ, Stewart D. Towards safer thrombolytic therapy. Semin Hematol 2002;39:206-16.